Learn More
BACKGROUND The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with(More)
e13524 Background: P53 is the most important tumor suppressor and it plays a key role in protection against malignant transformation. MDM2 and MDMX are important regulators of the transcriptional(More)
  • 1